BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 28323334)

  • 1. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M
    Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.
    Soung YH; Chung J
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    Xia M; Guo Z; Hu Z
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.